PAINCHEK LTD — AGM Information 2019

Nov 19, 2019

®

Philip Daffas CEO & MD AGM – 20[th] November 2019

PainChek Ltd ASX:PCK

PainChek™ Commercial in Confidence

1

PainChek® 2019 Highlights

▪ Accelerating SaaS sales and proven business model in Australia in Residential Aged Care

• Numerous case studies published & positive clinical outcomes reported

• Zero churn rate

• $5M Federal Government grant provides one-year universal access to all residents living with dementia in aged care

▪ International expansion

• Singapore direct sale 1[st] overseas agreement

• UK market entry – projected sales in Q4 C2019

• NZ sales projected Q4 C2019

▪ US FDA de-Novo classification for Dementia App

• Engagement with Human Factors and US population studies groups

• De Novo clearance projected late 2020/early 2021

• Patent granted in US – awaiting multiple countries including Europe, Japan and Australia

• Kids App clinical study engagement with Melbourne Children’s Hospital

• Philips HealthWorks program for hospital market opportunity

▪ Expansion of team capability and geographic locations

==> picture [7 x 8] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

==> picture [206 x 16] intentionally omitted <==

----- Start of picture text -----

PainChek™ Commercial in Confidence
----- End of picture text -----

The problem

==> picture [237 x 318] intentionally omitted <==

Pain assessment is difficult especially for those who cannot communicate such as dementia sufferers or infants/toddlers.

Pain is often under detected. Leading to under treatment and misdiagnosis.

This can lead to adverse impact on quality of care, operational efficiency and compliance

==> picture [236 x 316] intentionally omitted <==

==> picture [7 x 8] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

PainChek™ Commercial in Confidence

Our “Why”

==> picture [237 x 318] intentionally omitted <==

Our purpose is to give a voice to people who cannot verbalise their pain

==> picture [115 x 213] intentionally omitted <==

==> picture [117 x 202] intentionally omitted <==

==> picture [236 x 316] intentionally omitted <==

4

PainChek™ Commercial in Confidence

Pain assessment in dementia care is ready for disruption

==> picture [152 x 81] intentionally omitted <==

----- Start of picture text -----

Abbey Pain
Scale
2003
----- End of picture text -----

==> picture [61 x 41] intentionally omitted <==

• Abbey Pain Scale (APS) and similar manual systems are the current standard of care in developed countries for assessment of pain in dementia patients

• Key inputs in the APS rely on significant amount of subjective measures that can vary greatly between practitioners/carers.

==> picture [230 x 170] intentionally omitted <==

• PainChek builds on the benefits of the APS, maintaining clinical practice while improving clinical process and brings it into the digital age by:

• Using video/AI to automate the facial expression assessment - eliminating subjectivity and improving accuracy

• Eliminating paperwork – all digital

• 42 data points with prompts = faster assessments

• Automatic logging of pain scores over time – monitor pain trends

• Integrates into medical records

==> picture [141 x 76] intentionally omitted <==

----- Start of picture text -----

PainChek®
2017
----- End of picture text -----

==> picture [141 x 243] intentionally omitted <==

• Helps Care homes meet accreditation standards and protect income and revenues

• The Inventor of APS, Dr Jennifer Abbey is on the PCK scientific

• advisory board and is an advocate for our technology

==> picture [7 x 8] intentionally omitted <==

----- Start of picture text -----

5
----- End of picture text -----

PainChek™ Commercial in Confidence

Australian Federal Government Support of $5m

• Aus Federal govt. has pledged $5m for PainChek to implement into Aus residential aged care market

• Government is paying for a 12 month subscription for up to 100k dementia beds

• Govt wants to aid rapid adoption of PainChek and thus increase the quality of care

• Aged care providers under the scheme will roll onto standard commercial SaaS contracts after 12 months

• First revenue from this program expected in Q4 CY19

==> picture [916 x 256] intentionally omitted <==

----- Start of picture text -----

Prof Jeff Hughes
CSO – PainChek
Channel 10 Perth Evening News – 29 April
Sky News – 30 April
6
Audience: 100,000+.
----- End of picture text -----

==> picture [206 x 16] intentionally omitted <==

----- Start of picture text -----

PainChek™ Commercial in Confidence
----- End of picture text -----

7

PainChek[®] accelerating growth in clients, bed licenses and clinical assessments

Contracted Annual Recurring Revenue (ARR) (A$m)

==> picture [917 x 349] intentionally omitted <==

----- Start of picture text -----

Contracted number of Residential Contracted Annual Recurring Revenue
Residential Aged Care Clients and
Aged Care Beds (CNRB) (ARR) (A$m)
Facilities Contracted
280 25000 24,170 1.02
1
250
20000
0.8
200
0.65
160 15000
0.59
0.6
150 142 12,011
10,590
10000
0.4
100
79
5000 0.18
50 34 36 0.2 0.14
18 26 23 30 1,789 2,542
0 0 0
Nov-19
Dec-18 Mar-19 Jun-19 Sep-19 Dec-19 Dec-18 Mar-19 Jun-19 Sep-19 Nov-19Dec-19 Dec-18 Mar-19 Jun-19 Sep-19 Dec-19Nov-19
Total Contract Clients Contract RAC Facilities
Millions
November Only November Only November Only
th th th
To 18 To 18 To 18
----- End of picture text -----*

▪ Over 66k assessments have been completed since launch and growing rapidly each month

*Represents annualised contracted value in the 2nd year of signed contracts of 2 or 3 year terms with the benefit of Fed Govt Grant funding in 1[st] year, assuming contracts are fully implemented and not terminated.

PainChek™ Commercial in Confidence

Diversified customer and partners

Example Aged Care Customers

==> picture [488 x 364] intentionally omitted <==

Advocates & Supporters

==> picture [171 x 51] intentionally omitted <==

==> picture [148 x 44] intentionally omitted <==

==> picture [111 x 62] intentionally omitted <==

==> picture [143 x 56] intentionally omitted <==

8

PainChek™ Commercial in Confidence

Integration partners

• We are integrated with most of the major aged care management systems used by more than 160,000 aged care beds in Australia and 50,000 beds in the UK

• Direct integration means data flows automatically into existing systems reducing duplication of data entry, enhancing patient care plans accuracy and positively impacting medication management

• Integration with existing systems is crucial for rapid adoption of our Enterprise offering

• Integration partners are also incentivized to aid adoption of PainChek via small trailing commission/revenue

==> picture [146 x 55] intentionally omitted <==

==> picture [185 x 48] intentionally omitted <==

==> picture [134 x 51] intentionally omitted <==

==> picture [117 x 56] intentionally omitted <==

==> picture [129 x 46] intentionally omitted <==

==> picture [118 x 79] intentionally omitted <==

==> picture [158 x 31] intentionally omitted <==

==> picture [206 x 16] intentionally omitted <==

----- Start of picture text -----

PainChek™ Commercial in Confidence
----- End of picture text -----

9

Update on Projected Product Launch Dates

• Initial Market entry with Enterprise versions to validate utility with Health Care Professionals (HCP) sector and build value

• ▪ Direct to Carer (DTC) market expansion when HCP support in place and DTC training materials

Product Type	Aus Launch	EU Launch	US Launch
Enterprise Dementia	Late 2017	Oct 2019	Early 2021
Direct to Carer Dementia	Late 2020	Late 2020	Early 2021
Enterprise Pre-Verbal Children	Late 2020	Early 2021	Mid 2021
Direct to Carer Pre-Verbal Children	Early 2021	Mid 2021	Late 2021

PainChek™ Commercial in Confidence

10

==> picture [108 x 108] intentionally omitted <==

Philip Daffas CEO & Managing Director, MBA, BSc

Philip is a highly accomplished global business leader and people manager. Philip has held senior global leadership positions with Cochlear and Roche in Europe, US and Australia.

==> picture [111 x 111] intentionally omitted <==

Scott Robertson Chief Technology Officer, MBA, B.Eng. (Comp. Systems)

Scott has over 25 years’ experience designing, deploying and managing enterprise software systems. adapting to changing client needs,.

==> picture [108 x 108] intentionally omitted <==

Prof. Jeff Hughes Chief Scientific Officer PhD, MPS

Jeff is a professor in the School of Pharmacy, Curtin University in Western Australia.. Jeff is one of the team who developed the PainChek® concept.

==> picture [110 x 111] intentionally omitted <==

David Allsopp Head of Business Development ANZ

David has extensive account management, relationship management. He is renowned for establishing trusting, transparent and longstanding relationships in the healthcare space.

==> picture [107 x 108] intentionally omitted <==

Mustafa Atee Research Scientist MPS, PhD (candidate)

Mustafa is a clinical, community and academic pharmacist. The PainChek® concept was born out of his PhD research.

==> picture [116 x 116] intentionally omitted <==

Pete Shergill Business Development Director, UK

Pete is a UK Healthcare business leader and pharmacist with over 15 years of experience across Health and Social Care. Previous senior commercial roles with Lloyds Pharmacy UK and I-Care UK - a major residential aged care software provider

11

PainChek™ Commercial in Confidence

==> picture [166 x 167] intentionally omitted <==

----- Start of picture text -----

John Murray
Chairman
----- End of picture text -----

==> picture [167 x 167] intentionally omitted <==

Philip Daffas

John Murray

CEO & Managing Director

Non- Exec Chair

25 years in tech and Venture Capital. Philip is a highly accomplished global Founder of Technology Venture business leader and people manager. Partners, ex Chair of Residential Aged Senior medical device and diagnostics Care provider. Multiple non-exec healthcare executive roles have board roles. included, Global Marketing Director for Roche Diagnostics based in Germany, LLB, Member of Institute of Chartered Cochlear European Sales and Accountants of Scotland, MAICD. Marketing Director based in UK and Cochlear VP Global Marketing based in Sydney.

MBA, BSc, GAICD.

==> picture [166 x 169] intentionally omitted <==

Ross Harricks

Non-Exec Director

Senior global medical device executive with Nucleus group.

30 years experience in the international medical device industry - working in Europe, USA, and now Australia, in sales/marketing, CEO, President, Board member roles.

BE (Mech) MBA INSEAD

==> picture [166 x 168] intentionally omitted <==

Adam Davey

Non-Exec Director

Corporate finance executive with extensive capital markets experience

Accredited securities dealer in Australian and international shares and managed funds, fixed interest and margin lending and holds the Professional Diploma of Stockbroking.

PainChek™ Commercial in Confidence

12

®

Philip Daffas CEO & MD AGM – 20[th] November 2019

PainChek Ltd ASX:PCK

PainChek™ Commercial in Confidence

13